-
公开(公告)号：US20240327512A1
公开(公告)日：2024-10-03
申请号：US18597372
申请日：2024-03-06
申请人： Duke University , Ludwig-Maximilians Universität München , Deutsches Zentrum für Neurodegenerative Erkrankungen e. V.
发明人： Daniel Saban , Chen Yu , Christian Haass , Kai Schlepckow
CPC分类号： C07K16/2803 , A61K45/06 , A61P27/02 , G01N33/5058 , G01N33/6854 , A61K2039/505 , C07K2317/34 , C07K2317/565 , C07K2317/76 , G01N2333/70503
摘要： The present disclosure describes, in part, methods for treating a degenerative and vascular disease of the retina and/or posterior segment of the eye in a subject, the method comprising administering to a subject an effective amount of an antibody or fragment thereof that binds to the same epitope as an antibody comprising a heavy chain variable region and a light chain variable region, wherein: (a) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 4 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 5 wherein the antibody inhibits TREM2 cleavage; or (b) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 6 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO:7, and wherein the antibody inhibits TREM2 cleavage; or (c) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 8 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO:9 or to SEQ ID NO:87, and wherein the antibody inhibits TREM2 cleavage; or (d) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 10 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO:11 or to SEQ ID NO:12 or to SEQ ID NO:13 or to SEQ ID NO:14, and wherein the antibody inhibits TREM2 cleavage. and methods of screening for a molecule which specifically binds to and inhibits cleavage of human TREM2 between His157 and/or Ser158 on the surface of retinal microglial cells by ADAM10 and/or ADAM17.
-
2.发明公开公开(公告)号：US20240272152A1
公开(公告)日：2024-08-15
申请号：US18566899
申请日：2022-06-10
IPC分类号： G01N33/543 , G01N33/532 , G01N33/58
CPC分类号： G01N33/54388 , G01N33/532 , G01N33/581 , G01N33/582
摘要： The invention relates to a labeling DNA nanostructure for providing a signal amplifying detectable label in immunoassays, a test device, in particular a lateral flow test device, which comprises the labeling DNA nanostructure, a method for producing the labeling DNA nanostructure or the test device.
-
公开(公告)号：US11958880B2
公开(公告)日：2024-04-16
申请号：US17853591
申请日：2022-06-29
CPC分类号： C07K1/1075 , C12P21/005 , C12P21/02 , C12Y603/02025
摘要： The present invention provides means and methods for equipping a polypeptide of interest at its C-terminus with a versatile adaptor amino acid that allows the functionalization of the polypeptide of interest.
-
4.发明公开公开(公告)号：US20240047065A1
公开(公告)日：2024-02-08
申请号：US18264437
申请日：2022-02-09
申请人： INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITÉ PARIS CITÉ , UNIVERSITY OF DUNDEE , TECHNICAL UNIVERSITY OF DRESDEN , LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN , UNIVERSITY OF BIRMINGHAM , THE UNIVERSITY COURT OF THE UNIVERSITY OF GLASGOW
发明人： Maria-Christina ZENNARO , Emily JEFFERSON , Parminder Singh REEL , Smarti REEL , Graeme Eisenhofer , Martin REINCKE , Félix BEUSCHLEIN , Angela Elizabeth TAYLOR , Wiebke ARLT , Katharina LANG , Alessandro PRETE , Scott MACKENZIE , Eleanor DAVIES
IPC分类号： G16H50/20
CPC分类号： G16H50/20
摘要： The disclosed invention relates to a method for identifying biomarkers for the stratification of hypertensive patients among different hypertension diseases: endocrine forms of hypertension and primary hypertension. The method is a machine-learning based method using one trained classifier on a predefined input dataset to rank several combinations of omics biomarkers (miRNA, steroids, metanephrines, small metabolites) on the basis of the computation of at least one evaluation parameter. A combination of biomarkers is selected to stratify the hypertensive patient among said plurality of hypertension diseases. Also, the disclosed invention relates to a method for stratifying hypertensive patients, such as hypertensive patients with endocrine forms of hypertension (EHT). The method comprises operating a trained classifier on a combination of biomarkers determined from the hypertensive patient to stratify the hypertensive patient among several types of hypertensive patients such as endocrine forms of hypertension and primary hypertension.
-
公开(公告)号：US11723922B2
公开(公告)日：2023-08-15
申请号：US15768301
申请日：2016-10-14
发明人： Sebastian Kobold , Stefan Endres , Moritz Rapp , Simon Grassmann
IPC分类号： C12N5/10 , A61K35/17 , C07K14/715 , C12N15/86 , C07K14/725 , C07K14/705 , C12N5/0783 , C12N5/16 , C12N15/85 , A61P35/00 , A61K39/00
CPC分类号： A61K35/17 , C07K14/7051 , C07K14/70521 , C07K14/7158 , C12N5/0636 , C12N5/16 , C12N15/85 , C12N15/86 , A61K2039/5158 , A61P35/00 , C12N2510/00 , C12N2740/13043
摘要： The present invention relates to CXCR6-transduced (a) T cell(s) such as (a) CD8+ T cell(s), (a) CD4+ T cell(s), (a) CD3+ T cell(s), (a) γδ T cell(s) or (a) natural killer (NK) T cell(s) for targeted tumor therapy, nucleic acid sequences, vectors capable of transducing such (a) T cell(s), (a) transduced T cell(s) carrying the nucleic acid sequences or vectors of the present invention, methods and kits comprising the nucleic acid sequences or vectors of the present invention. The invention also provides the use of said transduced T cell(s) in a method for the treatment of diseases characterized by CXCL16 overexpression as well as a pharmaceutical composition/medicament comprising (a) transduced T cell(s) expressing the CXCR6 for use in methods of treating diseases characterized by CXCL16 overexpression.
-
公开(公告)号：US20230001477A1
公开(公告)日：2023-01-05
申请号：US17756219
申请日：2020-11-20
IPC分类号： B22F1/17 , B22F1/0545 , B22F1/065 , B22F1/102 , B22F1/145
摘要： The invention relates to a method of making a functionalized nanoparticle in an aqueous solution, wherein a chemical functionalization of a metal nanoparticle in the aqueous solution is provided and the aqueous solution comprises water and ingredients. The ingredients comprise at least the metal nanoparticle, a thiol of the form R—SH, where R represents a substituent, and a silver compound. The invention further relates to a plurality of functionalized nanoparticles according to the method, wherein each of the plurality of functionalized nanoparticles comprises a metal core, a silver coating and a sulfide bond substituent. The invention also relates to a lateral flow test method and device.
-
公开(公告)号：US20220332737A1
公开(公告)日：2022-10-20
申请号：US17616701
申请日：2019-06-05
发明人： Thomas CARELL
IPC分类号： C07F9/6521 , C07D251/16 , C12Q1/6886
摘要： The present invention relates to novel hydrolytically stable carbon-cyclic 5-aza-2-deoxycytidine and carbocyclic 5-aza-cytidine compounds and pro-drugs thereof as hypomethylating agents.
-
公开(公告)号：US20220296718A1
公开(公告)日：2022-09-22
申请号：US17626463
申请日：2020-07-10
IPC分类号： A61K47/18 , C07K16/32 , A61K39/395 , A61K38/21 , A61K38/19 , A61K38/20 , A61K47/02 , A61K47/22 , A61K47/12 , C07K16/28 , C07K16/42
摘要： The present invention relates to excipients for stabilizing active agents, in particular peptides, polypeptides, nucleic acids, viruses, virus-like particles, proton pump inhibitors and antibiotics. The excipient reduces aggregate and/or particle formation in preparations comprising said agents. The excipient is a diamide of a dicarboxylic acid comprising at least one N—H amido group, at least one unsubstituted or substituted N-hydroxyethylamido group and/or at least one unsubstituted N-hydroxymethylamido group. In particular, the excipient is N,N,N′,N′-tetrakis-(2-hydroxyethyl) adipinic acid amide.
-
公开(公告)号：US20220265782A1
公开(公告)日：2022-08-25
申请号：US17631221
申请日：2020-07-16
发明人： Gerhard WINTER , Simon EISELE , Sonja MOLINARO , Wolfgang MUTTER
摘要： The present invention relates to compositions comprising a therapeutic protein with enhanced stability, which comprise a piperazine- or morpholine-containing zwitterionic buffering substance, such as HEPES, in particular when used out of the common pH range. The compositions of the invention are particularly useful for topical administration The present invention further relates to the use of said compositions for treating bacterial infections, e.g. bacterial infections caused by Staphylococcus aureus such as methicillin-resistant Staphylococcus aureus (MRSA). The present invention further relates to the use of said compositions for preventing or eliminating nasal bacterial colonization or bacterial colonization of the skin.
-
公开(公告)号：US20220106356A1
公开(公告)日：2022-04-07
申请号：US17460791
申请日：2021-08-30
发明人： Christian Hackenberger , Marc André Kasper , Maria Glanz , Tom Sauer , Dominik Schumacher , Jonas Helma-Smets , Heinrich Leonhardt , Andreas Stengl
摘要： Disclosed are novel conjugates and processes for the preparation thereof. A process for the preparation of alkene- or alkyne-phosphonamidates comprises the steps of (I) reacting a compound of formula (III) with an azide of formula (IV) to prepare a compound of formula (V) (II) reacting a compound of formula (V) with a thiol-containing molecule of formula (VI) resulting in a compound of formula (VII)
-
-
-
-
-
-
-
-
-
搜索结果
88 条记录 (耗时 0.028 秒)
